Here you will find press releases, an image bank and can subscribe to our releases. If you do not find what you are looking for, do not hesitate to contact us.
- Bulletin from Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)09 October 2019 - Regulatory press release
- Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)19 September 2019 - Regulatory press release
- InDex Pharmaceuticals has completed a directed share issue of approximately SEK 140 million (USD 14 million)19 September 2019 - Regulatory press release
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.Learn more